Name that brand

Share this article:

Can you name the brand? Each month we print part of a popular pharmaceutical product or advertisement, along with some clues to its identity. Readers are invited to name the brand for a chance to win a copy of Medicine Avenue II. Please e-mail your answer to NameThatBrand@haymarketmedia.com or fax 646-638-6150. The deadline is November 30, 2011. The winner will be selected randomly from all the correct entries.

Brand X settles an uncomfortable issue

November's Brand X puts a hex on a condition that causes unease in around 25 million American adults. But since a host of other drugs try to do so as well, the marketers behind this one tried to break out of the pack with a colorful campaign that illustrates the range of disagreeable symptoms sufferers may experience—a “3 Bs” approach that emphasizes the “many places” that the disease may strike. At the moment, the manufacturer is pumping up the volume with an offer of a free two-week trial supply of the drug.

SEPTEMBER'S  WINNER...
No one was able to correctly identify September's Name That Brand. The answer was Novartis's Reclast, a drug administered once a year by IV to combat postmenopausal osteoporosis.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?